Gastrointestinal Imaging

What Is the Best Imaging for HCC Screening in Chronic Liver Disease?

·
What Is the Best Imaging for HCC Screening in Chronic Liver Disease?

A 62-year-old man with a history of cirrhosis secondary to nonalcoholic steatohepatitis (NASH) presents for his routine six-month follow-up. He is asymptomatic, and his liver function tests are stable. You know that guidelines recommend regular surveillance for hepatocellular carcinoma (HCC), but you need to decide on the most appropriate initial imaging test. This is a common decision point where selecting the right modality balances diagnostic yield with patient safety and resource utilization. This article details the American College of Radiology (ACR) Appropriateness Criteria workflow for this exact scenario: screening and surveillance for HCC in a patient with chronic liver disease and no prior cancer diagnosis. For this presentation, the ACR designates US abdomen as a Usually Appropriate first-line imaging study.

Who Fits This Clinical Scenario for HCC Surveillance?

This guidance applies specifically to adult patients with established chronic liver disease who are at high risk for developing hepatocellular carcinoma but have no prior diagnosis of HCC. The primary goal is either screening (the first imaging test for this purpose) or surveillance (the ongoing, scheduled imaging at regular intervals).

Inclusion criteria for this workflow:

  • Patients with cirrhosis from any etiology, including viral hepatitis (B or C), alcohol-associated liver disease, or nonalcoholic steatohepatitis (NASH).
  • Certain patients with chronic hepatitis B infection without cirrhosis, based on specific risk factors (e.g., age, family history, viral load).

It is critical to distinguish this scenario from similar but distinct clinical questions. This workflow does not apply to:

  • Patients with a known or treated HCC: These individuals require post-treatment monitoring, which follows a different imaging algorithm. This is covered in the ACR variant Chronic liver disease. Previous diagnosis of HCC. Post-treatment monitoring for HCC.
  • Patients needing initial fibrosis assessment: If the clinical question is to determine the presence or stage of liver fibrosis, rather than screen for cancer, the appropriate scenario is Chronic liver disease. Diagnosis and staging of liver fibrosis. Initial imaging.
  • Patients with acute liver injury or fulminant hepatic failure: These are emergent situations with a different diagnostic urgency and workup.

What Diagnoses Are You Working Up in This Scenario?

While the term “screening” implies looking for one thing, surveillance imaging of the cirrhotic liver assesses for a spectrum of changes. The primary goal is the early detection of malignancy when it is most treatable.

The most critical diagnosis to identify is Hepatocellular Carcinoma (HCC). HCC is the most common primary liver cancer and a leading cause of cancer-related death worldwide. Patients with cirrhosis have a substantially elevated risk, and surveillance is proven to detect tumors at an earlier stage, improving outcomes and eligibility for curative therapies like resection, ablation, or liver transplantation.

Imaging also aims to detect Dysplastic Nodules. These are precancerous lesions that can progress to HCC. Identifying high-grade dysplastic nodules allows for closer monitoring and potential intervention before malignant transformation occurs. While distinguishing low-grade dysplastic nodules from benign regenerative nodules can be challenging, tracking their size and characteristics over time is a key component of surveillance.

Finally, the examination provides an updated assessment of the stigmata of portal hypertension and the overall morphology of the cirrhotic liver. This includes evaluating for ascites, splenomegaly, and the development of portosystemic collateral vessels (varices). These findings inform the overall management of the patient’s liver disease, independent of the cancer screening goal.

Why Is Ultrasound the Recommended Study for HCC Surveillance?

The ACR designates US abdomen as Usually Appropriate for HCC screening and surveillance, making it the standard first-line examination. The rationale is based on a favorable balance of accessibility, safety, and diagnostic capability for this specific task.

Ultrasound is non-invasive, widely available, relatively inexpensive, and does not use ionizing radiation (0 mSv). This safety profile is paramount in a surveillance context, where patients will undergo repeated imaging studies every six months for many years. Its primary role is to detect focal liver lesions. If a new or growing nodule is found, the patient can then proceed to more definitive diagnostic imaging.

While ultrasound is the primary modality, other studies are also rated highly but reserved for specific situations:

  • MRI abdomen without and with IV contrast and MRI abdomen without and with hepatobiliary contrast are also rated Usually Appropriate. MRI offers higher sensitivity for detecting and characterizing small liver lesions compared to ultrasound. However, it is more costly, less accessible, and requires more time to perform. It is often used as the next step to evaluate a suspicious finding on ultrasound or may be considered as a primary surveillance tool in select high-risk patients or those in whom ultrasound is technically limited.
  • CT abdomen with IV contrast multiphase is rated May be appropriate (Disagreement). While multiphase CT is excellent for characterizing liver lesions, its use for routine surveillance is debated due to the significant cumulative radiation dose (☢☢☢☢ 10-30 mSv) over a patient’s lifetime. It serves as a valuable alternative for patients who cannot undergo MRI.

Studies like US shear wave elastography and MR elastography are rated Usually not appropriate for this specific scenario. Their purpose is to quantify liver stiffness to stage fibrosis, not to screen for focal masses. While a patient undergoing surveillance likely had elastography in the past to establish their diagnosis, it is not the correct test for ongoing HCC monitoring.

What’s Next After US abdomen? Downstream Workflow

The results of a surveillance ultrasound dictate the next steps, which are typically guided by the Liver Imaging Reporting and Data System (LI-RADS).

  • Negative or Benign Result (LI-RADS 1 or 2): If the ultrasound shows no new lesions or only demonstrates definitively benign findings (e.g., a simple cyst), the patient should continue their standard surveillance schedule. The recommendation is to repeat the ultrasound and serum alpha-fetoprotein (AFP) test in six months.
  • Indeterminate or Subthreshold Nodule (LI-RADS 3): If a small nodule (<1 cm) is found that does not have definitively benign features, the risk of malignancy is low but not zero. The standard approach is a short-interval follow-up ultrasound, often in three months, to assess for stability or growth.
  • Suspicious Nodule (LI-RADS 4 or 5 Observation): For a new or growing nodule ≥1 cm, or one with suspicious features, the ultrasound is considered positive. This result should trigger a diagnostic examination with a multiphase, contrast-enhanced study. The preferred modality is typically multiphase MRI, with multiphase CT as a strong alternative. The goal of this second study is to definitively characterize the lesion and, if it is HCC, to stage it for treatment planning.
  • Inadequate Visualization: If the ultrasound is technically limited due to factors like severe steatosis, overlying bowel gas, or patient body habitus, the report should clearly state this. In such cases, continuing with ultrasound for surveillance may be unreliable. The ordering clinician should consider using an alternative modality, such as MRI or CT, for future surveillance examinations.

Pitfalls to Avoid (and When to Get Help)

Effective HCC surveillance requires careful attention to both imaging and clinical context. Here are common pitfalls to avoid:

  • Accepting a non-diagnostic study: Do not continue ordering surveillance ultrasounds if prior reports consistently state the liver was poorly visualized. This provides a false sense of security.
  • Ignoring ancillary findings: Pay attention to new or worsening signs of portal hypertension, such as increasing ascites or spleen size, as this may signal decompensation requiring a change in clinical management.
  • Forgetting the AFP: While this article focuses on imaging, most major societal guidelines (including the AASLD) recommend pairing surveillance ultrasound with a serum alpha-fetoprotein (AFP) blood test every six months to maximize sensitivity.
  • Inappropriate workup of benign lesions: Familiarize yourself with classic benign findings like cysts and hemangiomas to avoid ordering unnecessary and costly follow-up studies.

If an ultrasound is repeatedly non-diagnostic or if a suspicious lesion is identified, it is time to escalate. This typically involves referring the patient for a diagnostic multiphase CT or MRI and consulting with a hepatologist or gastroenterologist to guide further management.

Related ACR Topics and Tools

This article covers one specific clinical scenario. For a comprehensive overview of imaging for all related presentations, please see our parent guide. For additional tools to help refine your imaging orders, see the resources below.

For breadth across all scenarios in Chronic Liver Disease, see our parent guide: Chronic Liver Disease: ACR Appropriateness Decoded.

Frequently Asked Questions

How often should imaging surveillance for HCC be performed?

For patients with cirrhosis or other high-risk conditions, most major societal guidelines recommend surveillance imaging every six months. Shorter intervals have not been shown to improve outcomes and increase costs, while longer intervals may miss the window for detecting early-stage, treatable tumors.

Should I order an ultrasound with or without serum alpha-fetoprotein (AFP)?

The American Association for the Study of Liver Diseases (AASLD) and other major guidelines recommend performing both an abdominal ultrasound and a serum AFP test every six months. Combining both tests increases the sensitivity for detecting early-stage HCC compared to using either test alone.

What if my patient is obese and the ultrasound quality is poor?

This is a common and significant limitation. If an ultrasound report states the study was technically limited or the liver was not fully visualized, you should not rely on it for surveillance. In these cases, the ACR criteria suggest that alternative cross-sectional imaging, such as MRI or multiphase CT, may be appropriate for surveillance, despite their higher cost and potential risks (e.g., radiation with CT).

Is an MRI or CT better for working up a suspicious nodule found on ultrasound?

Both multiphase CT and MRI are excellent diagnostic tests for characterizing liver lesions. MRI is generally considered to have slightly higher sensitivity and specificity for HCC, especially for smaller lesions, and avoids ionizing radiation. Therefore, MRI is often the preferred next step if there are no contraindications (like incompatible hardware or severe claustrophobia). Multiphase CT is a highly effective and widely available alternative.

Why isn’t elastography (like FibroScan or MRE) used for HCC surveillance?

Elastography measures liver stiffness to assess the degree of fibrosis or cirrhosis. It answers the question, ‘How much scarring does the liver have?’ It is not designed to detect or characterize focal liver masses. Once a patient is known to have cirrhosis and is enrolled in an HCC surveillance program, the clinical question shifts from staging fibrosis to finding cancer. For that task, standard grayscale ultrasound is the appropriate screening tool.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026